Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; DCOG-LATER Q2008 study; Long-term renal effects in Dutch survivors of childhood cancer

Completed

• Conditions: late nefrotoxic effects of treatment for childhood cancer; renal damage in long-term survivors of childhood cancer; 10038430

• Registration Number: NL-OMON47761
• Lead Sponsor: Stichting Kinderoncologie Nederland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 2000

Inclusion Criteria

All patients who were treated for childhood cancer (before age 18) in one of
the seven Pediatric Oncology Centers between 1960 and 2004 and who survived for
at least 5 years after diagnosis will be included in the SKION LATER study.
Participating centres are located in Amsterdam (VU University Medical Center
(VUMC)), Groningen (Children's Cancer Center/ University Medical Center
Groningen (UMCG)), Rotterdam (Rotterdam Erasmus MC-Sophia (REMC-S), Nijmegen
(University Medical Center Nijmegen (UMCN)), Leiden (Leiden University Medical
Center (LUMC) and Utrecht (Princess Máxima Center for Pediatric Oncology
(PMC)).
From this cohort, 2000 childhood cancer survivors who previously received
potentially nefrotoxic treatment will be asked to participate in the DCOG-LATER
Q2008 nefrology study.

Exclusion Criteria

diagnosis of childhood cancer with survival less than 5 years, age at diagnosis
>18 years or diagnosed while residing in foreign country, no nefrotoxic
treatment

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1) Prevalence of glomerular dysfunction in 5-year survivors of childhood cancer<br /><br>treated with possible nefrotoxic modalities (comparisons: high<br /><br>risk versus low-risk group; high-risk group versus reference values from<br /><br>general population; low riskgroup versus reference values general<br /><br>population)<br /><br>2) Prevalence of tubular dysfunction in 5 year CCS treated with potential<br /><br>nefrotoxic therapy (comparisons: high<br /><br>risk versus low-risk group; high-risk group versus reference values from<br /><br>general population; low riskgroup versus reference values general<br /><br>population)<br /><br>3) Treatment related-risk factors for abnormal diagnostic renal fucntion tests<br /><br>4) Hypertension (in relation to glomerular function)<br /><br>5) Diagnostic value of Cystatin C voor glomerular dysfunctie<br /><br></p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>